Standard treatment of advanced-stage diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma and is not localized in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic parameters are different from one patient to another, the standard treatment is the same for all patients. Currently, treatment decision is based on the International Prognostic Index (IPI) and age of the patient. Outcome has been completely modified with the introduction of rituximab in combination with chemotherapy. A review of standard treatment and remaining questions is presented.
Coiffier
Bertrand
B
Hospices Civils de Lyon and Université Claude Bernard, Lyon, France. betrand.coiffier@chu-lyon.fr
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone